Results 51 to 60 of about 55,278 (277)
Diabetes, Obesity and Metabolism, EarlyView.Abstract Aims Type 2 diabetes (T2D) is a highly heterogeneous disease characterised by subtypes with variations in aetiology, disease progression, and risk of complications. However, potential drug targets for these subtypes have not been explored. This study aims to investigate potential drug targets by integrating proteomics.
Jiahe Wei +8 more
wiley +1 more source
The FEBS Journal, EarlyView.The Leishmania phosphatase PTP1, and possibly the genetically similar PTP2, interacts with the Leishmania transmembrane protein DUF21. When both ptp1 and ptp2 are knocked out of Leishmania (LdΔPTP1/2), the parasite can no longer survive without magnesium in vitro and has reduced viability in the host macrophage. Conversely, in duf21 knockout (LdΔDUF21),
Kayla Paulini +6 more
wiley +1 more source
Artificial intelligence‐powered microscopy: Transforming the landscape of parasitology
Journal of Microscopy, EarlyView.Abstract Microscopy and image analysis play a vital role in parasitology research; they are critical for identifying parasitic organisms and elucidating their complex life cycles. Despite major advancements in imaging and analysis, several challenges remain. These include the integration of interdisciplinary data; information derived from various model
Mariana De Niz +4 more
wiley +1 more source
Detection of Leishmania DNA in wild foxes and associated ticks in Patagonia, Argentina, 2000 km south of its known distribution area [PDF]
, 2016 Indexación: Web of Science; PubMedBackground: Zoonotic Visceral Leishmaniasis (ZVL) is a vector-borne disease affecting humans and other mammals and caused by the protozoan parasite Leishmania (Leishmania) infantum (syn. L.
Ferroglio, Ezio +6 more
core +4 more sources
Journal of Microscopy, EarlyView.Abstract Kinetoplastid parasites include several species. Trypanosoma brucei causes African sleeping sickness in humans and a wasting disease nagana in livestock. Trypanosoma cruzi is the causative agent of Chagas disease and Leishmania species cause leishmaniasis, which can present with visceral, cutaneous, or mucocutaneous symptoms.
Heidi Anderson +2 more
wiley +1 more source
Interest in paromomycin for the treatment of visceral leishmaniasis (kala-azar)
Therapeutics and Clinical Risk Management, 2012 Viroj Wiwanitkit1–31Wiwanitkit House, Bang Khae, Bangkok, Thailand; 2Hainan Medical University, Haikou, Hainan, People's Republic of China; 3Joseph Ayo Babalola University, Ikeji-Arakeji, Osun State, NigeriaAbstract: Leishmaniasis is an
Wiwanitkit V
doaj
Case Reports in Infectious Diseases, 2014 Leishmaniasis is a tropical infection caused by the protozoan, belonging to the group of Leishmania which causes Old World and New World disease. These are typically divided into cutaneous, mucocutaneous, visceral, viscerotropic, and disseminated disease.
Cyriac Abby Philips +4 more
doaj +1 more source
International Journal of Infectious Diseases, 2019 Eighty years after the last published record of human leishmaniasis from Dagestan, Russian Federation, we report two recent cases which were most probably acquired locally: one case of visceral leishmaniasis in a 2-year old child, and one cutaneous ...
Sergey Andreevich Nagorny +6 more
doaj +1 more source
Journal of Interventional Epidemiology and Public Health, 2022 Introduction: Leishmaniasis currently threatens 350 million men, women and children around the world. Visceral leishmaniasis (VL) is a fatal parasitic disease mostly prevalent in low land areas VL typically affects migrant agricultural workers.
Sisay Awoke +3 more
doaj +1 more source
Visceral Leishmaniasis Treatment, Italy [PDF]
Emerging Infectious Diseases, 2003 First-line drug treatment was recorded in 573 immunocompetent patients with visceral leishmaniasis in Italy. In the past 12 years, the proportion of antimonial treatments decreased from 100% to 2.8%, while the proportion of amphotericin B treatments increased from 0% to 97.2%.
Luigi Gradoni +2 more
openaire +3 more sources